Cardiovascular and Metabolic Diseases (CVD) remain the number one cause of death worldwide.
In recent decades there have been remarkable reductions in death from cardiovascular diseases, largely due to a decreased prevalence of smoking and modern science that has led to effective therapies for hypertension and high cholesterol. Even so, cardiovascular diseases (CVD) remain the number one cause of death worldwide.
The modern lifestyle has promoted a new array of cardiovascular risk factors…
CVD continues as an epidemic, driven by a number of factors, including the rising rates of obesity and its resulting metabolic diseases, such as type 2 diabetes mellitus and the metabolic syndrome, which refers to the group of risk factors that increase an individual’s risk for heart disease and other health problems.2 The modern lifestyle has promoted a new array of cardiovascular risk factors, but treatments for these have remained elusive. We believe that a comprehensive program is needed to address the collection of diseases of the cardiovascular system, as well as their root causes, including obesity and metabolic disease.
T-ON is focused on investigating potential therapies that treat both the metabolic abnormalities that increase the likelihood of cardiovascular disease and the heart itself…
For more than 50 years, T-ON has led the way in redefining the management of cardiovascular risk by bringing much-needed treatments to patients.
Today, T-ON is focused on investigating potential therapies that treat both the metabolic abnormalities that increase the likelihood of cardiovascular disease and the heart itself by trying to alter the way it responds to the abnormal metabolic state. This includes more targeted potential therapies, as well as possible therapies that are a combination of two or more drugs, which could bring additional benefits to patients.
Our early discovery efforts focus on emerging areas of CV research such as control of eating disorders, type 2 diabetes/muscle uptake of glucose and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
Creating a medicine involves lots of scientists, working together across multiple sites, not only looking to discover new breakthrough compounds, but also coming up with innovative ways to help patients take medicines in the most effective way possible.
In fact, how we take medicines and their very design are essential parts of the process.
Do we take it as a tablet / capsule or as a liquid? How do we know it will reach the right part of the body? How often do we need to take it?
Our site within Discovery Park, in Sandwich, UK, is a co-home (with Groton, CT, USA) to our Medicinal Sciences, Pharmaceutical Sciences Small Molecule team. This team uses its specialist expertise to turn experimental molecules into the liquid and solid dose medicines used in clinical trials.